Scoping review shows WHO Access antibiotic susceptibility remains low in Pakistan clinical isolates
This scoping review synthesizes evidence from 74 studies conducted in Pakistan regarding human clinical isolates. The scope focuses on the susceptibility of WHO Access antibiotics, specifically aminoglycosides, beta lactams, and cephalosporins. The authors examine trends in antimicrobial resistance patterns within this specific setting without reporting adverse events or tolerability data.
The main synthesized finding indicates that susceptibility of WHO Access antibiotics remained low across major pathogens. However, the review notes notable declines in susceptibility for S. aureus and Pseudomonas spp. In contrast, susceptibility of E. coli showed variable results across the included studies. No specific effect sizes, absolute numbers, or p-values were reported for these outcomes.
The authors highlight that safety data, including adverse events and discontinuations, were not reported in the source materials. Funding or conflicts of interest were also not reported. The review acknowledges that strengthening surveillance programs is essential to curb antimicrobial resistance and align national efforts with global antibiotic use targets. This practice relevance underscores the need for continued monitoring rather than immediate clinical guideline changes based on this synthesis alone.